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Abstract:  We  previously  showed  that  plasminogen  (Plg)  isolated  from  the  plasma  of 
normal  human subjects  contains  1–2 moles  of  oxidized phosphatidylcholine (oxPtdPC) 
adducts/mole of protein. Moreover, we suggested that these species are generated at the 
hepatic  site  and  speculated  that  they  may  play  a  role  in  the  reported  cardiovascular 
pathogenicity  of  Plg.  We  aimed  to  determine  whether  mouse  Plg  also  harbors  linked 
oxPtdPCs  and  whether  these  molecules  are  metabolized  by  lipoprotein-associated 
phospholipase  A2/PAF  acetylhydrolase  (Lp-PLA2/PAF-AH),  an  enzyme  specific  for 
hydrolysis of oxPtdPCs. We determined the total concentration of Plg in plasma samples 
from control (WT) and Lp-PLA2-deficient (KO) mice, we isolated Plg, and assessed its 
content  of  oxPtdPCs  by  immunoblot  analyses.  We  also  evaluated  whether  human 
recombinant Lp-PLA2 metabolized Plg-linked oxPtdPCs in vivo and in vitro. WT and KO 
mice expressed comparable levels  (14.4–15.8 mg/dL) of plasma Plg, as determined by 
ELISA. We observed no differences in the content of oxPtdPC in Plg isolated from the two 
mouse  strains  and  in  parallel  no  changes  in  oxPtdPC  content  in  mouse  Plg  following 
incubation with pure recombinant  Lp-PLA2. Plg from mouse plasma contains oxPtdPC 
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adducts that are not affected by the action of Lp-PLA2, suggesting that linkage to Plg 
protects oxPtdPCs from metabolism during their transport in the plasma. This modification 
may  have  important  physio-pathological  implications  related  to  the  function  of  Plg, 
oxPtdPCs, or both. 
Keywords:  mouse  plasminogen;  oxidized  phosphatidylcholine;  lipoprotein-associated 
phospholipase A2; oxidized phopholipids 
 
1. Introduction  
We  previously  showed  that  oxidized  phosphatidylcholine  (oxPtdPC)  is  chemically  linked  to 
naturally occurring human apolipoprotein (a) [apo(a)] and that this linkage involves 1 to 2 lysines in 
kringle V located in the C-terminal domain of this apolipoprotein [1]. We subsequently showed that 
oxPtdPCs are linked to apo(a) in a 2:1 ratio that is not affected by plasma Lp(a) levels or apo(a) size 
polymorphisms [2]. We also reported that in healthy subjects, linked oxPtdPCs do not originate from 
plasma LDL or the LDL component of Lp(a) [2]. Recently, we reported that naturally occurring human 
Plg, a multi-kringle structure that shares structural and genetic features with apo(a), contains about 
2 mol of oxPtdPCs/mol [3]. We also showed that human HepG2 cells secrete Plg containing linked 
oxPtdPCs, [3] suggesting that these modified lipids are covalently linked to Plg in the liver [2]. 
The purpose of the present study was to determine whether mouse Plg, which is 79% homologous 
to  human  Plg,  contains  linked  oxPtdPCs  and  whether  these  oxidized  lipid  species  are  subject  to 
metabolism by lipoprotein-associated phospholipase A2 (Lp-PLA2) [4]. This enzyme, also known as 
platelet-activating factor (PAF) acetylhydrolase (PAF-AH) has specificity for hydrolysis of sn-2 acyl 
groups present in biologically active phospholipids such as PAF and oxPtdPCs, and has been proposed 
to have both pro- and anti-inflammatory functions [5]. Previous studies were focused on the ability of 
Lp-PLA2 to hydrolyze free and non-covalently-bound, lipoprotein-associated oxPtdPCs in human [6] 
and mouse [7,8] plasma. Thus, the issue of whether Lp-PLA2 metabolizes oxPtdPC-protein adducts, 
particularly in in vivo settings, is a novel area of investigation.  
2. Results  
2.1. Plasminogen from WT and KO Mice  
The  concentration  of  Plg  in  the  plasma  of  WT  and  KO  mice  as  determined  by  ELISA  was  
15.8 ±  1.2 and 14.4 ±  1.3 mg/dL, respectively (mean ±  SD of four determinations in duplicate from 
four mice). From each plasma sample, Plg was isolated by lysine-Sepharose affinity chromatography. 
In both cases, the product contained a single band migrating in the same position as standard Plg when 
analyzed on 4–12% SDS-PAGE gradient gels stained with Coomassie Blue (Figure 1A). In addition, 
Plg samples from WT and KO mice reacted against anti-mouse Plg (Figure 1B).  Int. J. Mol. Sci. 2010, 11                       
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2.2. Mouse Plasminogen Contains Covalently Linked OxPtdPCs 
To evaluate whether mouse Plg contained OxPtdPCs we subjected Plg isolated from WT and KO 
mice to immunoblot analyses using T15. We found that both sets of samples reacted strongly with the 
OxPtdPC-specific monoclonal antibody (Figure 1B). Pre-treatment with denaturing agents, extraction 
with organic solvents and 1–2 cycles of freezing/thawing failed to affect T15 reactivity (not shown). 
These results indicated that OxPtdPCs are covalently linked to Plg. 
Figure 1. Purification of mouse Plg. (A) Coomassie-stained gel depicting the behavior of 
purified mouse Plg from WT and KO mice on a non-reduced 4–12% SDS-PAGE gel. Lane 
KO, 5 µg of protein applied; lane WT, 2 µg of protein applied; comm. mouse Plg, 5 µg of 
protein applied; (B) Immunoblot of purified Plg from a commercial source and from WT 
and KO mice, probed with anti-mouse Plg antibodies and T15. 
 
2.3. Lp-PLA2 Does Not Cleave OxPtdPC Linked to Plasminogen 
To investigate whether Plg-bound oxPtdPCs are metabolized by Lp-PLA2 in vitro we incubated Plg 
isolated from WT and KO
 mouse plasma with a pure, enzymatically active, preparation of human  
Lp-PLA2. Both sets of samples exhibited the same T15 reactivity as incubated (24 h at 37 ° C), but 
untreated,  controls  (Figure  2).  These  in  vitro  studies  strongly  suggested  that  Lp-PLA2  does  not 
metabolize oxPtPC linked to Plg.  Int. J. Mol. Sci. 2010, 11                       
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Figure  2.  Lp-PLA2 does  not  metabolize OxPtdPCs  linked to Plg. A, T15 immunoblot  
of mouse Plg from WT and KO mice, before and after 5 h and 24 h incubations with  
active Lp-PLA2. 
 
To further investigate this issue, we quantified the oxPtdPC molecules bound to Plg isolated from 
WT and KO mice by ELISA (see “Methods”) (Figure 3A). The assay was highly reproducible over a 
wide range of concentrations (1.56 to 100 nmol/L, Figure 3B). From the values obtained we calculated 
an oxPtdPC:Plg ratio of one for both Plg samples, establishing that under basal conditions, deletion of 
Lp-PLA2 does not affect the extent of Plg conjugation with oxPtdPCs. 
Figure 3. Sandwich ELISA for detection of Plg-bound OxPtdPC. (A) We developed a 
sandwich ELISA for the detection of OxPtdPC linked to Plg in which T15 was the capture 
antibody and anti-mouse Plg conjugated to HRP was the detection antibody. (B) Dose 
response curve obtained with purified mouse Plg. Vertical bars through the data points 
represent means ±  SD.  
 
3. Experimental Section  
3.1. Materials and Methods 
The studies in mice were carried out in strict accordance with the recommendations in the Guide for 
the  Care  and  Use  of  Laboratory  Animals  of  the  National  Institutes  of  Health.  The  protocol  was 
approved by the committee on the Ethics of Animal Experiments of the University of UTAH (animal 
welfare assurance number A3031-01). Int. J. Mol. Sci. 2010, 11                       
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3.2. Materials 
BSA,  Tween-20,  SDS,  ε-amino  caproic  acid,  4-(2-Aminoethyl)-benzene  sulfonylfluoride,  and  
N-α-tosyl-L-lysine  chloromethylketone  hydrochloride  were  from  Sigma-Aldrich  Chemical  Co. 
(St. Louis, MO, USA). Immobilon-P membranes were from Millipore Corp. (Billerica, MA, USA) and 
Superblock  blocking  buffer  and  the  Supersignal
®  West  Dura  Extended  Duration  Substrate  were 
purchased from Thermo Scientific (Rockford, IL). Coomassie staining solution (Page Blue) was from 
Fermentas  Inc.  (Glen  Burnie,  MD,  USA).  Precast  acrylamide  gels  were  from  Invitrogen  Corp. 
(Carlsbad, CA, USA). All chemicals were of reagent grade.  
Human  recombinant  Lp-PLA2  (Pafase
®)  was  a  generous  gift  from  ICOS  Corporation  (Bothell,  
WA, USA). 
3.3. Antibodies 
The murine T15 antibody-secreting cell line, BH8 (IgM) that reacts with oxPtdPC antigens was a 
gift from Dr. John F. Kearney (University of Alabama) and is heretofore referred to as T15. This cell 
line  was  maintained  in  the  Frank  W.  Fitch  Antibody  Facility  of  the  University  of  Chicago.  The 
antibodies in the culture medium were isotyped and contained a high titer of IgM antibodies (greater 
than 90%) as verified by the major Coomassie stained band on SDS-PAGE. 
Affinity purified rabbit anti-mouse Plg polyclonal antibodies were obtained from Cell Sciences 
(Canton, MA, USA). Horseradish peroxidase (HRP)-labeled secondary antibodies [goat anti-mouse 
IgM (μ chain specific) and donkey anti-rabbit IgG] were from Sigma-Aldrich. 
3.4. Plasminogen Isolation and Quantitation 
Plasma from healthy mice was utilized to purify Plg using the procedure of Deutsch and Mertz [9], 
followed by purification on G25 Sepharose columns. We also employed commercial preparations of 
mouse  Plg  purchased  from  Enzyme  Research  Laboratories  (South  Bend,  IN,  USA).  Quantitative 
determination of Plg in mouse plasma and in purified samples was conducted using an ELISA kit 
(Kamiya  Biomedical  Co.,  Seattle,  WA,  USA).  The  Plg  standard  concentrations  ranged  from  6.25  
to 200 ng/mL.  
3.5. Delipidation of Plasminogen 
Lipids  were  extracted  from  purified  Plg  by  a  modified  Bligh  and  Dyer  method  [10]  in  that 
chloroform was replaced by anhydrous diethyl ether in a ratio of 1:2 v/v (ether:methanol). Plg in 
0.8 mL  50  mM  Tris-HCl  containing  0.1  M  NaCl,  pH  7.4  was  added  to  the  ethyl  ether-methanol 
mixturedropwise and rotated at 4 ° C for 6 h. The mixture was then centrifuged and the precipitated 
protein washed three times with diethyl ether. The washed precipitate was dried with argon gas and 
dissolved in the Tris buffer. The protein recovery was close to 85% of the original starting material. 
An alternative delipidation technique was also carried out using a 3:2 v/v mixture of ethanol:diethyl 
ether  as  already  published  for  apo(a)  [1].  In  both  delipidation  techniques  the  Plg  was  soluble  in 
aqueous buffers.  Int. J. Mol. Sci. 2010, 11                       
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3.6. Electrophoretic Methods 
SDS-PAGE (gradients of 4–12% polyacrylamide) was performed on
 a Novex system (Novex, San 
Diego, CA) for 1.5 h at constant
 voltage (120 V) at 22 ° C, as described [1,2]. The samples were 
prepared by heating at 95 ° C for 5 min in sample buffer [94 mM phosphate buffer (pH 7.0), 1% SDS 
and 2 M urea, with or without 3% mercaptoethanol]. Following electrophoresis, the gels were placed 
on Immobilon-P
 sheets (Millipore Corp., Bedford, MA) previously wetted in 48 mM Tris, 39 mM 
glycine (pH 8.9). Blotting was performed on a horizontal semi-dry electroblot apparatus (Amersham 
Biosciences) at 0.8–1 mA/cm
2 for 45 min at 23 ° C. 
3.7. Immunoblot Analyses 
After electroblotting, the Immobilon-P sheets were blocked in Superblock (Thermo Scientific, Inc. 
Rockford, IL. USA) for 1 h at 23 ° C followed by incubation with rabbit anti-mouse Plg IgG or, in the 
case of T15, by incubation in 10% Superblock for 18 h at 4 ° C. Bound antibodies were visualized 
using secondary antibodies conjugated to HRP; donkey anti-rabbit IgG for Plg, and goat anti-mouse 
IgM (μ-chain specific) for oxPtdPC. The blots were developed with Supersignal
® West Dura Extended 
Duration Substrate from Thermo Scientific, Inc. (Rockford, IL).  
3.8. T15 ELISA for Quantitation of OxPtdPC 
We utilized a novel sandwich ELISA by which we measured T15 immunoreactivity in Plg isolated 
from mouse plasma. Polystyrene microtiter plates (flat-bottom 96-well EIA plates) were coated with 
100  µL  of  T15  [400  ng/well,  dissolved  in  TBS  buffer  [50  mmol/L  Tris-HCl,  0.15  mol/L  NaCl 
(pH 7.5)] and incubated overnight at room temperature, in 10 mmol/L Tris, 0.15 mol/L NaCl (pH 7.6). 
Unbound antibodies were removed by washing with TBS supplemented with 0.1% BSA and 0.02% 
Tween-20. Non-specific binding sites were blocked with 1% BSA in TBS for 1.5 h. After three washes 
with TBS supplemented with 0.02% Tween-20 (TBST), we added 100 µL of each dilution of the 
mouse  Plg  standard  and  samples  (diluted  in  TBST)  and  incubated  the  plates  for  2  h  at  room 
temperature. After three washes with TBST, bound Plg was detected by incubation with a specific, 
HRP-conjugated anti-mouse Plg polyclonal antibody for 1 h in TBST. The wells were washed three 
times with TBST, the chromogenic substrate 3,3',5,5'-tetramethylbenzidine was added and, after an 
appropriate incubation period at room temperature, the reactions were stopped with 3 mol/L H2SO4. 
T15  immunoreactivity  was  quantitated  by  assessing  the  absorbance  at  450  nm  using  a  Versamax 
microplate reader (Molecular Devices, Sunnyvale, CA). The concentrations of the Plg standard ranged 
from 1.56 to 100 nmol/L. 
3.9. Defining T15 Equivalents 
Based on the standard curve, the absorbance of each sample reacting with T15 was converted to 
nmol/L of Plg. This number was divided by the concentration (nmol/L) of Plg in each mouse sample. 
This ratio was defined as the “T15 equivalent”.  Int. J. Mol. Sci. 2010, 11                       
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3.10. Targeted Disruption of the Mouse Lp-PLA2 (Pla2g7) Gene 
The generation of Pla2g7
−/− mice took place at the University of Utah and was recently described in 
detail [11] Briefly, a targeting vector lacking exons 3 and 4 of the mouse Pla2g7 gene was introduced 
into embryonic stem cells and a resulting chimeric male was bred to C57BL/6J females. The progeny 
was genotyped as previously described [11].  
3.11. Incubation of Mouse Plg with Lp-PLA2 
Mouse Plg (1 to 3 µg) was incubated with recombinant Lp-PLA2 (4 µg) in PBS for up to 24 h at 
37 ° C. The reactions were stopped with Pefabloc and the samples were stored frozen at −20 ° C until 
subsequent analyses.  
4. Discussion 
A novel finding of our current studies was that freshly isolated mouse Plg and commercial sources 
contain  chemically  linked  oxPtdPCs.  The  chemical  linkage,  likely  of  the  Schiff  base  nature,  was 
suggested by the observations that T15 immunoreactivity was present in fresh and frozen samples, was 
not  altered by extensive delipidation  with organic solvents  or by boiling in  the presence of SDS. 
Of note, our observations were made under basal, unstimulated conditions, and paralleled our previous 
results  in  both  apo(a)  and  Plg  isolated  from  normal  human  plasma  [2,3].  Together,  our  findings 
challenge the belief that oxPtdPC generation only occurs in response to pro-oxidant/pro-inflammatory 
events which would presumably be quite limited in healthy subjects and in unstimulated mice [4]. 
A plausible  explanation  is  that  adduct  formation  occurs  during  early,  pre-secretory  stages  of  Plg 
generation. In previous studies we proposed a model whereby the syntheses of human apo(a) [1] and 
human Plg [3] may be accompanied, or shortly followed, by oxPtdPC linkage to newly synthesized 
proteins.  We  now  speculate  that  the  liver  provides  a  minimally  pro-oxidant/pro-inflammatory 
microenvironment  exquisitely  sensed  by  a  lysine  residue(s)  in  the  Plg  molecule,  leading  to  the 
formation of oxPtdPC-Plg adducts.  
A second novel observation from quantitative and metabolic standpoints was that the extent of Plg 
conjugation with oxPtdPC was not affected by Lp-PLA2. This suggests that under basal conditions,  
Lp-PLA2 does not play a critical role in the metabolism of Plg-bound oxPtdPCs during transport in the 
circulation.  Lack of activity may be due to  peculiar Plg conformations that prevent  the candidate 
linkage sites from interacting with Lp-PLA2, an interpretation consonant with in vitro studies in which 
oxPtdPC was not cleaved when mouse Plg was incubated with Lp-PLA2. We recognize that in our  
in vitro studies we utilized a recombinant rather than a naturally occurring Lp-PLA2 that, in the mouse 
plasma, under normal conditions is expected to be essentially all bound to HDL [4]. We believe, 
however, that the validity of our in vitro experiments is supported by the results of our in vivo studies 
in KO mice. In our previous study, cleavage of oxPtdPCs linked to human Plg occurred but only under 
conditions of a high enzyme to substrate ratio and prolonged times of incubation [3].  
Further studies are needed to determine whether the number of oxPtdPCs linked to Plg increases in 
settings of elevated oxidant and/or inflammatory stress and to assess whether Lp-PLA2 modulates this 
process.  These  analyses  may  provide  important  clues  to  explain  why  Plg  has  pathological Int. J. Mol. Sci. 2010, 11                       
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cardiovascular properties, an issue emerging from recent studies in Plg-deficient mice [12]. In this 
regard,  plasma  from  transgenic  mice  expressing  human  apo(a)  contain  Lp(a)/apo(a)  with  bound 
oxPtdPCs proposed to contribute to uremia-induced atherosclerosis [13,14]. However, the potential 
contribution by the oxPtdPC-Plg adducts cannot be ruled out. Considering our observation that Plg is 
the major oxPtdPC carrier in the circulation, contrary to an early belief [15], we may speculate that Plg 
modulates OxPtdPC metabolism in the circulation, in physiological and possibly pathological settings. 
In the current and previous studies, the number of linked oxPtdPCs was limited to 1 or 2. In the case 
of apo(a), the modification involved specific microdomains within kringle V [1,3], suggesting that a 
kringle repeat(s) may also participate in linkage of OxPtdPCs to Plg. Under physiological conditions it 
is possible that the formation of Plg adducts reflects a mechanism to shield potential pro-inflammatory 
OxPtdPCs from metabolism during transport in the circulation. To rigorously test this, it would be 
ideal  to  compare  the  properties  of  Plg  adducts  harboring  various  amounts  of  oxPtdPCs. 
Unfortunately, given  the  chemical  nature  of  the  oxPtdPC-Plg  linkage,  the  lipid  component  is  not 
amenable to extraction  by  organic  solvents;  drastic  procedures  would  likely  result  in  denatured, 
unsuitable  bio-products.  Also  unfortunate  is  the  fact  that  Lp-PLA2  cannot  be  utilized  to  generate 
OxPtdPC-free Plg. Mutagenic approaches should prove useful, but it will be necessary to first identify 
the oxPtdPC linkage site on Plg. 
5. Conclusions 
In  conclusion,  under  physiological  conditions,  mouse  Plg,  like  its  human  counterpart,  carries 
chemically linked oxPtdPCs  that are not  cleaved by  Lp-PLA2, an enzyme known to  be active on 
oxidized phospholipids associated with plasma lipoproteins. Future studies will elucidate the molecular 
basis for lack of recognition and/or metabolism of Plg-bound oxPtdPCs by Lp-PLA2. These studies 
should  provide  a  platform  to  assess  possible  relationships  between  oxPtdPCs,  Plg,  and  
Lp-PLA2  under  stressed  and  pathological  conditions.  Work  along  these  lines  may  have  broad  
physio-pathological  implications,  including  issues  related  to  the  function  of  the  pro-atherogenic 
lipoprotein Lp(a). 
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